Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7710932

CCCCNCC.O=C(O)C(F)(F)F

nearest known ligand 0.58

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.58
FUCA1 P04066 1/20 0.46
EPHX1 P07099 1/20 0.46
CYP2C19 P33261 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GLA P06280 1/20 0.42
FAAH O00519 8/20 0.42
ALOX15 P16050 1/20 0.42
CYP1A2 P05177 2/20 0.41
CES1 P23141 5/20 0.41
CES2 O00748 2/20 0.41
HSD17B10 Q99714 1/20 0.41
CA3 P07451 2/20 0.39
CA5A P35218 2/20 0.39
CA5B Q9Y2D0 2/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL10701644 0.92 EPHX1 (0.56) TSHREPHX1MEN1KMT2AFAAH
Trifluoroacetic Acid SCHEMBL3928477 0.91 FUCA1 (0.49) TSHRFUCA1EPHX1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL28395953 0.87 FAAH (0.50) FUCA1EPHX1MEN1KMT2AFAAH
Trifluoroacetic Acid SCHEMBL5494836 0.83 FAAH (0.47) FUCA1EPHX1MEN1KMT2AFAAH
Acetic Acid SCHEMBL5571306 0.82 TSHR (0.70) TSHREPHX1CYP2C19MEN1KMT2A
Trifluoroacetic Acid SCHEMBL2242176 0.82 TP53 (0.44) FUCA1EPHX1MEN1KMT2AFAAH
Trifluoroacetic Acid SCHEMBL7024064 0.81 FUCA1 (0.47) FUCA1EPHX1MEN1KMT2AFAAH
Trifluoroacetic Acid SCHEMBL8529050 0.81 FUCA1 (0.47) FUCA1EPHX1MEN1KMT2AFAAH
SCHEMBL11113926 0.81 THRB (0.55) TSHRFUCA1EPHX1CYP2C19MEN1
Acetic Acid SCHEMBL29061342 0.80 TSHR (0.67) TSHREPHX1CYP2C19MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US claimed
US-20250066860-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK 2025-02-27 US disclosed
CN-111868260-B Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2025-02-21 CN disclosed
US-12195803-B2 Methods and materials for assessing and treating cancer THE JOHNS HOPKINS UNIVERSITY (US) 2025-01-14 US disclosed
US-20200377956-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2020-12-03 US disclosed
CN-111868260-A Methods and materials for assessing and treating cancer 约翰斯霍普金斯大学 2020-10-30 CN disclosed
EP-3665308-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER The Johns Hopkins University (US) 2020-06-17 EP disclosed
US-20190256924-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY 2019-08-22 US disclosed
WO-2019067092-A1 METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER THE JOHNS HOPKINS UNIVERSITY (US) 2019-04-04 WO disclosed
US-6361940-B1 IMMOBILIZATION; GENETIC ENGINEERING QIAGEN GENOMICS, INC. 2002-03-26 US disclosed
EP-0958378-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY Rapigene, Inc. (US) 1999-11-24 EP disclosed
EP-0952228-A2 Compositions and methods for enhancing hybridization specificity Rapigene, Inc. (US) 1999-10-27 EP disclosed
WO-1998013527-A2 COMPOSITIONS AND METHODS FOR ENHANCING HYBRIDIZATION SPECIFICITY RAPIGENE, INC. (US) 1998-04-02 WO disclosed